Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Current and upcoming treatment approaches to uncommon subtypes of PTCL (EATL, MEITL, SPTCL, and HSTCL)

Enrica Marchi, Jeffrey W. Craig, Matko Kalac

Blood (2024) 144 (18): 1898–1909.

https://doi.org/10.1182/blood.2023021788

Published: 2024

Includes: Supplemental data

Journal Articles

A Real World Experience of Combined Treatment with Romidepsin and Azacitidine in Patients with Peripheral T-Cell Lymphoma - a Bridge to Transplant and an Effective Salvage for the Unfit

Matko Kalac, Salvia Jain, Constantine S. Tam, Mendel Goldfinger, Zhengrui Xiao, Francesca Montanari, Bryan D. Huber, Jennifer A. Kanakry, Owen A. O'Connor, Enrica Marchi

Blood (2022) 140 (Supplement 1): 9422–9424.

https://doi.org/10.1182/blood-2022-165165

Published: 2022

Journal Articles

CD19-Targeted CAR T Cell Therapy for Concomitant Diffuse Large B Cell Lymphoma and Myeloma

Tyler J D'Ovidio, Kathryn Ciccolini, Matko Kalac, Keren Osman, Amir Steinberg

Blood (2021) 138 (Supplement 1): 4811.

https://doi.org/10.1182/blood-2021-147586

Published: 2021

Journal Articles

A Real World Experience of Combined Treatment with Romidepsin and Azacitidine in Patients with Peripheral T-Cell Lymphoma

Matko Kalac, Constantine S. Tam, Mendel Goldfinger, Zhengrui Xiao, Francesca Montanari, Jennifer A. Kanakry, Owen A. O'Connor, Enrica Marchi

Blood (2021) 138 (Supplement 1): 4550.

https://doi.org/10.1182/blood-2021-144651

Published: 2021

Journal Articles

Safety and Anti-Tumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

Craig H. Moskowitz, Mariana Bastos-Oreiro, MD PhD, David Ungar, MD, Ilva Dautaj, Matko Kalac, MD PhD

Blood (2019) 134 (Supplement_1): 2807.

https://doi.org/10.1182/blood-2019-128036

Published: 2019

Journal Articles

Constitutive Phosphorylation of CYLD Promotes ATLL Survival By Inhibiting RIPK1-Dependent Cell Death

Xin Xu, Matko Kalac, MDPhD, Michael Markson, Joshua Brody, MD, Govind Bhagat, Feng Liu, Qingshan Li, Adrian Ting, PhD

Blood (2018) 132 (Supplement 1): 1581.

https://doi.org/10.1182/blood-2018-99-117397

Published: 2018

Journal Articles

A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma

Jennifer E. Amengual, Renee Lichtenstein, Jennifer Lue, Ahmed Sawas, Changchun Deng, Emily Lichtenstein, Karen Khan, Laine Atkins, Aishling Rada, Hye A. Kim, Codruta Chiuzan, Matko Kalac, Enrica Marchi, Lorenzo Falchi, Mark A. Francescone, Lawrence Schwartz, Serge Cremers, Owen A. O’Connor

Blood (2018) 131 (4): 397–407.

https://doi.org/10.1182/blood-2017-09-806737

Published: 2018

Includes: Supplemental data

Journal Articles

Mini BEAM with Full-Dose of Melphalan (beaM) As a Conditioning Regimen for High Risk Patients with NHL Undergoing Autologous SCT

Matko Kalac, MD PhD, Cristine Candland, RN, Lisa Wallace, RN, Elizabeth Gentner, RN, Shreya Shah, Jennifer E Amengual, MD, Changchun Deng, MD PhD, Suzanne Lentzsch, MD PhD, Owen A. O'Connor, MD PhD, Markus Y Mapara, MD PhD

Blood (2016) 128 (22): 5834.

https://doi.org/10.1182/blood.V128.22.5834.5834

Published: 2016

Journal Articles

Targeting NF-κB with First in Class N-Quinoline Benzenesulfonamides (NQBS) Reveals Potent Activity in Models of Diffuse Large B-Cell Lymphoma (DLBCL)

Matko Kalac, MD PhD, Michael Mangone, PhD, Alison Rinderspacher, PhD, Shi-Xian Deng, PhD, Luigi Scotto, PhD, Jeremie Vendome, PhD, Mukesh Bansal, PhD, Andrea Califano, PhD, Donald Landry, MD PhD, Owen A. O'Connor, MD PhD

Blood (2015) 126 (23): 4435.

https://doi.org/10.1182/blood.V126.23.4435.4435

Published: 2015

Journal Articles

Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma

Jennifer E. Amengual, Sean Clark-Garvey, Matko Kalac, Luigi Scotto, Enrica Marchi, Ellen Neylon, Paul Johannet, Ying Wei, Jasmine Zain, Owen A. O’Connor

Blood (2013) 122 (12): 2104–2113.

https://doi.org/10.1182/blood-2013-02-485441

Published: 2013

Journal Articles

Sirtuin Inhibition in Combination with Histone Deacetylase (HDAC) Inhibition Is Effective Therapy for Aggressive B-Cell Lymphomas in Both Pre-Clinical and Clinical Studies of Disease.

Jennifer E Amengual, MD, Sean Clark-Garvey, Matko Kalac, MD, PhD, Luigi Scotto, PhD, Enrica Marchi, MD, PhD, Celests Rojas, Ellen Neylon, FNP, MSN, RN, OCN, Paul M Johannet, Salvia Jain, MD, Jasmine M. Zain, MD, Owen A. O'Connor, MD, PhD

Blood (2012) 120 (21): 2725.

https://doi.org/10.1182/blood.V120.21.2725.2725

Published: 2012

Journal Articles

Validation of a Novel Bioluminescent Mouse Model of Sezary Syndrome for Preclinical Drug Screening

Salvia Jain, MD, Luigi Scotto, Ph.D., Enrica Marchi, MD, Ph.D., Matko Kalac, MD, Ph.D., Jennifer Amengual, M.D., Jairo Baquero Buitrago, Owen A. O'Connor, MD, PhD

Blood (2011) 118 (21): 2725.

https://doi.org/10.1182/blood.V118.21.2725.2725

Published: 2011

Journal Articles

Combination of Epigenetic Agents Synergistically Reverse the Malignant Phenotype in Models of T-Cell Lymphoma

Enrica Marchi, MD, Ph.D., Matko Kalac, MD, Ph.D., Danielle C Bongero, Christine M McIntosh, Laura K Fogli, Luigi Scotto, Ph.D., Maura Rossi, Ph.D., Pier Luigi Zinzani, MD, PhD, Stefano Pileri, MD, Pier Paolo Piccaluga, Sr., MD, PhD, Owen A. O'Connor, MD, PhD

Blood (2011) 118 (21): 2727.

https://doi.org/10.1182/blood.V118.21.2727.2727

Published: 2011

Journal Articles

Therapeutic Targeting of the Bcl-6: p53 Axis with Histone Deacetylase Inhibitors in Diffuse Large B-Cell Lymphoma,

Jennifer E Amengual, MD, Matko Kalac, MD, Ph.D., Luigi Scotto, Ph.D., Patrick A Sleckman, Enrica Marchi, MD, Ph.D., Changchun Deng, MD, PhD, Danielle C Bongero, Salvia Jain, MD, Jairo Baquero Buitrago, Owen A. O'Connor, MD, PhD

Blood (2011) 118 (21): 3733.

https://doi.org/10.1182/blood.V118.21.3733.3733

Published: 2011

Journal Articles

HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL

Matko Kalac, Luigi Scotto, Enrica Marchi, Jennifer Amengual, Venkatraman E. Seshan, Govind Bhagat, Netha Ulahannan, Violetta V. Leshchenko, Alexis M. Temkin, Samir Parekh, Benjamin Tycko, Owen A. O'Connor

Blood (2011) 118 (20): 5506–5516.

https://doi.org/10.1182/blood-2011-02-336891

Published: 2011

Includes: Supplemental data

Journal Articles

The Combination of Histone Deacetylase Inhibitors and Hypomethylating Agents Exhibits Marked Synergy In Preclinical Models of T-Cell Lymphoma

Enrica Marchi, MD, Ph, D, Danielle C Bongero, Matko Kalac, MD, PhD, Luigi Scotto, Ph.D., Owen A. O'Connor, MD, PhD

Blood (2010) 116 (21): 3937.

https://doi.org/10.1182/blood.V116.21.3937.3937

Published: 2010

Journal Articles

Generation and Characterization of a Novel CD19-CherryLuciferase (CD19CL) Mouse Model: A New Fluorescent/Bioluminescent Model for the Study of B-Cell Development and Lymphomagenesis

Luigi Scotto, Ph.D., Marianna Kruithof de Julio, Ph.D., Luca Paoluzzi, MD, Matko Kalac, MD, Ph.D., Enrica Marchi, MD, Ph.D., Jairo Baquero Buitrago, BS, Owen A. O'Connor, MD, Ph.D.

Blood (2010) 116 (21): 3940.

https://doi.org/10.1182/blood.V116.21.3940.3940

Published: 2010

Journal Articles

Synergistic Combinations of Histone Deacetylase Inhibitors and Decitabine Induce a Unique Gene Expression and Epigenetic Profile In Models of Diffuse Large B-Cell Lymphoma

Matko Kalac, M.D., Ph.D., Enrica Marchi, M.D., Ph.D., Luigi Scotto, Ph.D., Jennifer Amengual, M.D., Venkatraman Seshan, Govind Bhagat, M.D., Netha Ulahannan, Violetta Leshchenko, Ph.D., Samir Parekh, M.D., Benjamin Tycko, M.D., Ph.D., Owen A. O'Connor, M.D., Ph.D.

Blood (2010) 116 (21): 435.

https://doi.org/10.1182/blood.V116.21.435.435

Published: 2010

Journal Articles

Histone Deacetylase Inhibitors Synergistically Enhance the Cytotoxic Effect of Hypomethylating Agents in Models of Diffuse Large B-Cell Lymphoma.

Matko Kalac, MD, Yukiko Kitagawa, MD, PhD, Seshan Ennapadam Venkatraman, Benjamin Tycko, MD, PhD, Owen A O'Connor, MD, PhD

Blood (2009) 114 (22): 3720.

https://doi.org/10.1182/blood.V114.22.3720.3720

Published: 2009

Journal Articles

Febrile Neutropenia Following Autologous Stem Cell Transplantation in Patients with Lymphoma

Radovan Vrhovac, Zinaida Peric, Matko Kalac, Alen Ostojic, Visnja Kovacevic, Suzana Bukovski-Simonoski, Arjana Tambic-Andrasevic, Hrvoje Minigo, Branimir Jaksic

Blood (2008) 112 (11): 4379.

https://doi.org/10.1182/blood.V112.11.4379.4379

Published: 2008

NARROW

Current and upcoming treatment approaches to uncommon subtypes of PTCL (EATL, MEITL, SPTCL, and HSTCL)

A Real World Experience of Combined Treatment with Romidepsin and Azacitidine in Patients with Peripheral T-Cell Lymphoma - a Bridge to Transplant and an Effective Salvage for the Unfit

CD19-Targeted CAR T Cell Therapy for Concomitant Diffuse Large B Cell Lymphoma and Myeloma

A Real World Experience of Combined Treatment with Romidepsin and Azacitidine in Patients with Peripheral T-Cell Lymphoma

Safety and Anti-Tumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

Constitutive Phosphorylation of CYLD Promotes ATLL Survival By Inhibiting RIPK1-Dependent Cell Death

A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma

Mini BEAM with Full-Dose of Melphalan (beaM) As a Conditioning Regimen for High Risk Patients with NHL Undergoing Autologous SCT

Targeting NF-κB with First in Class N-Quinoline Benzenesulfonamides (NQBS) Reveals Potent Activity in Models of Diffuse Large B-Cell Lymphoma (DLBCL)

Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma

Sirtuin Inhibition in Combination with Histone Deacetylase (HDAC) Inhibition Is Effective Therapy for Aggressive B-Cell Lymphomas in Both Pre-Clinical and Clinical Studies of Disease.

Validation of a Novel Bioluminescent Mouse Model of Sezary Syndrome for Preclinical Drug Screening

Combination of Epigenetic Agents Synergistically Reverse the Malignant Phenotype in Models of T-Cell Lymphoma

Therapeutic Targeting of the Bcl-6: p53 Axis with Histone Deacetylase Inhibitors in Diffuse Large B-Cell Lymphoma,

HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL

The Combination of Histone Deacetylase Inhibitors and Hypomethylating Agents Exhibits Marked Synergy In Preclinical Models of T-Cell Lymphoma

Generation and Characterization of a Novel CD19-CherryLuciferase (CD19CL) Mouse Model: A New Fluorescent/Bioluminescent Model for the Study of B-Cell Development and Lymphomagenesis

Synergistic Combinations of Histone Deacetylase Inhibitors and Decitabine Induce a Unique Gene Expression and Epigenetic Profile In Models of Diffuse Large B-Cell Lymphoma

Histone Deacetylase Inhibitors Synergistically Enhance the Cytotoxic Effect of Hypomethylating Agents in Models of Diffuse Large B-Cell Lymphoma.

Febrile Neutropenia Following Autologous Stem Cell Transplantation in Patients with Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only